| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1353-8020(09)70776-X |
| P8608 | Fatcat ID | release_a2kohjzcobda7h4acs5is6efhq |
| P698 | PubMed publication ID | 20083003 |
| P2093 | author name string | William J Weiner | |
| P2860 | cites work | Clinical trials in rheumatic diseases: designs and limitations | Q35920275 |
| Initial treatment of Parkinson disease: levodopa or dopamine agonists | Q35982508 | ||
| Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology | Q36445093 | ||
| Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology | Q36445098 | ||
| Minority enrollment in Parkinson's disease clinical trials | Q37236732 | ||
| Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study | Q39360937 | ||
| Reflections on controlled trial | Q39932250 | ||
| A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease | Q40254829 | ||
| Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease | Q40434081 | ||
| Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease | Q42165505 | ||
| Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial | Q46378100 | ||
| A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease | Q46947253 | ||
| Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group | Q51375126 | ||
| Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration | Q51911689 | ||
| De Testimonio: on the evidence for decisions about the use of therapeutic interventions. | Q51942363 | ||
| Initiating therapy in Parkinson's disease | Q53106575 | ||
| Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group | Q53958979 | ||
| Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report | Q56689283 | ||
| Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group | Q64869758 | ||
| Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I | Q67220188 | ||
| Design considerations for AIDS trials | Q68564250 | ||
| Short-term beneficial effect of deprenyl monotherapy in early Parkinson's disease: a quantitative assessment | Q70535221 | ||
| An additional basic science for clinical medicine: II. The limitations of randomized trials | Q71058899 | ||
| Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists | Q80691664 | ||
| Are excellent systematic reviews of clinical trials useful for patient care? | Q81227751 | ||
| Evidence based medicine: what it is and what it isn't | Q24655756 | ||
| Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 | Q28244224 | ||
| Risperidone treatment of drug-related psychosis in patients with parkinsonism | Q28375634 | ||
| 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group | Q29619952 | ||
| Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology | Q30793529 | ||
| Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials | Q31033537 | ||
| Systematic reviewers commonly contact study authors but do so with limited rigor | Q33384805 | ||
| Report of the health care delivery work group: behavioral research related to the establishment of a chronic disease model for diabetes care | Q34149222 | ||
| Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease | Q34358956 | ||
| Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors | Q34389549 | ||
| A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study | Q34555070 | ||
| The causes and effects of socio-demographic exclusions from clinical trials | Q34561109 | ||
| Representation of the elderly, women, and minorities in heart failure clinical trials | Q34769936 | ||
| Neuroprotection trials in Parkinson's disease: systematic review | Q34913056 | ||
| Parkinson's disease: is the initial treatment established? | Q35203983 | ||
| Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. | Q35215657 | ||
| Association of dopamine agonist use with impulse control disorders in Parkinson disease | Q35567194 | ||
| P304 | page(s) | S34-7 | |
| P577 | publication date | 2009-12-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Parkinsonism and Related Disorders | Q15762600 |
| P1476 | title | What do clinical trials tell us about treating patients? | |
| P478 | volume | 15 Suppl 3 |
| Q38817972 | Clinical Pharmacokinetics and Pharmacodynamics of Safinamide |
| Q37369674 | Clinical and economic burden of adverse drug reactions |
| Q38064971 | Drug therapy in patients with Parkinson’s disease |
| Q26740905 | Emerging approaches in Parkinson's disease - adjunctive role of safinamide |
| Q33636631 | New small molecules for the treatment of Parkinson's disease |
| Q38947507 | Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective |
| Q39325939 | Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease |
| Q38011428 | Psychiatric, nonmotor aspects of Parkinson's disease |
| Q52804779 | Safinamide: an add-on treatment for managing Parkinson's disease |
Search more.